Trospium chloride

Description

Trospium chloride (Sanctura) is an antimuscarinic that has been used in Europe for the management of OAB symptoms for over 30 years.Trospium chloride's chemical structure is such that it is unlikely to penetrate the brain and thus does not appear to affect cognitive function. Trospium chloride is usually administered orally twice a day in 20mg. Trospium chloride should be taken 1 hour before meals or on an empty stomach. It is not well absorbed if taken with food.An advantage of this medication is that it has little potential interaction with other medications.

Chemical properties

White to Off-White Crystalline Solid

Originator

Keptan,Muller

The Uses of Trospium chloride

Tropine derivative with anticholinergic activity, Trospium chloride can be used as Antispasmodic and used in treatment of urinary incontinence

The Uses of Trospium chloride

An antimuscarinic compound that inhibits mAChR M

The Uses of Trospium chloride

Labeled Trospium, intended for use as an internal standard for the quantification of Trospium by GC- or LC-mass spectrometry.

What are the applications of Application

Trospium Bromide is an antimuscarinic compound that blocks action at mAChR M

What are the applications of Application

Trospium Chloride is an antimuscarinic compound that inhibits mAChR M

Definition

ChEBI: Trospium chloride is an organic chloride salt of trospium. It is an antispasmodic drug used for the treatment of overactive bladder. It has a role as a muscarinic antagonist and an antispasmodic drug. It is an organic chloride salt and a quaternary ammonium salt. It contains a trospium.

Manufacturing Process

12.7 g of nortropine and 21.6 g 1,4-dibrombutane are heated, with stirring,for 14 hours at 38-40°C in 200 ml 70% ethanol in the presence of a strongly basic ion exchanger. The reaction mixture is filtered, the filtrate brought to a pH of 4-5 by addition of dilute hydrochloric acid, then evaporated to dryness in a vacuum. The residue crystallized from ethanol-ether. Azoniaspiro-(3α- hydroxy-nortropan-8,1'-pyrrolidine) chloride is obtained in a yield of about 51%; melting point 294-297°C.
2.17 g azoniaspiro-(3α-hydroxy-nortropan-8,1'-pyrrolidine) chloride and 4.24 g acetyl mandelic acid chloride are heated in a vacuum (12 mm Hg) for 6n hours at 100°C. After the addition of 40 ml water, the reaction mixture is repeatedly extracted, the aqueous phase adjusted to pH 6.7-6.8 and continuously extracted with chloroform for 24 hours. After the addition of 20 ml concentrated hydrochloric acid, the residue of the chloroform extract is left to stand for 15 hours at room temperature. The hydrochloric acid is then removed in a vacuum, the residue taken up in absolute ethanol, filtered through aluminum oxide. The filtrate evaporated to dryness and the residue crystallized from methanol-acetone. Azoniaspiro(3α-benziloyloxy-nortropan- 8,1'-pyrrolidine)-chloride is obtained in a yield of about 20%; melting point 197-198°C.

brand name

Sanctura (Indevus).

Therapeutic Function

Anticholinergic, Spasmolytic

General Description

Trospium chloride, 3α-benziloyloxynortropane-8-spiro-1'-pyrrolidinium chloride, (Sanctura) was available in Europe for almost 20 years before gainingapproval in the United States in May 2004. Much likeoxybutynin, it too is a competitive antagonist for muscarinicreceptors and is used to manage overactive bladder. Thequaternary amine reduces the likelihood that this agent willcross the blood-brain barrier. In addition, it has a limitedmetabolic profile, largely a result of its highly water-solublecharacteristics.

Clinical Use

Antimuscarinic:
Symptomatic treatment of urinary incontinence, frequency or urgency

Drug interactions

Potentially hazardous interactions with other drugs
Anti-arrhythmics: increased risk of antimuscarinic side effects with disopyramide.

Metabolism

The metabolic pathway of trospium in humans has not been fully defined. Of the 10
% of the dose absorbed, metabolites account for approximately 40
% of the excreted dose following oral administration. The major metabolic pathway is hypothesised as ester hydrolysis with subsequent conjugation of benzylic acid to form azoniaspironortropanol with glucuronic acid.
The mean renal clearance for trospium (29 L/hour) is 4-fold higher than average glomerular filtration rate, indicating that active tubular secretion is a major route of elimination for trospium. There may be competition for elimination with other compounds that are also renally eliminated.